Intratumoral Sotigalimab with Pembrolizumab Activates Antigen Presenting cells and Induces Local and Distant Anti Tumor Responses in First line Metastatic Melanoma: Results of a Phase I/II Study
Distinct Biosignatures Associate with Survival After Chemoimmunotherapy in a Randomized, Three-arm Phase II Study in Patients with Metastatic Pancreatic Cancer
Intratumoral CD40 Agonist Sotigalimab (APX005M) with Pembrolizumab Induces Broad Innate and Adaptive Immune Activation in Local and Distant Tumors in Metastatic Melanoma
First in Pediatrics Phase 1 Study Of CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors
A Phase 1b Study of CD40 Agonistic Monoclonal Antibody APX005M Together with Gemcitabine and nab-Paclitaxel with or without Nivolumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Patients
First in Human Study with the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors
